Galapagos raising cash for new buyouts

Belgium's Galapagos is raising about $43 million in a new offering designed to help fund new acquisitions. Galapagos bought Argenta earlier this year for €16.5 million. "Management also remains ambitious to make Galapagos a European biotech leader, and acquisitions may help us to achieve that goal," said CEO Onno van de Stolpe. Story

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.